(Q36361160)

13 August 2017

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

1 reference

Colm Farrell

1

1 reference

13 August 2017

Charles Schweizer

2

1 reference

13 August 2017

Jason Wustner

3

1 reference

13 August 2017

Susan Weil

4

1 reference

13 August 2017

Masayuki Namiki

5

1 reference

13 August 2017

Tomohisa Nakano

6

1 reference

13 August 2017

Kenya Nakai

7

1 reference

13 August 2017

Martin D Phillips

8

1 reference

13 August 2017

7 September 2012

1 reference

Cancer Chemotherapy and Pharmacology

13 August 2017

1 reference

13 August 2017

70

1 reference

13 August 2017

5

1 reference

13 August 2017

727-734

1 reference

Characterization of the human folate receptor alpha via novel antibody-based probes

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Clinical pharmacokinetics of therapeutic monoclonal antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Folate receptor alpha as a tumor target in epithelial ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Overexpression of folate binding protein in ovarian cancers.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485533

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study

28 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-012-1959-Y

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-012-1959-Y

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-012-1959-Y

Effective half-life in clinical pharmacology

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22955257

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22955257

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22955257

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-012-1959-Y

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22955257

1 reference